




HIV AND INJECTION DRUG USE IN MARYLAND, 2023

DATA REPORTED THROUGH JUNE 30, 2024

New HIV Diagnoses in Maryland


In 2023, there were 30 reported HIV diagnoses among persons with IDU exposure.

- Of the 714 reported HIV diagnoses in 2023, 4.2% were attributed to IDU exposure and 0.8% were among people with MMSC/IDU exposure.
- Of the 551 male and 163 total female HIV diagnoses, 3.2% and 7.4%, respectively, were attributed to IDU exposure.
- It is estimated that an additional 1.1% of persons with IDU exposure living with HIV in Maryland remain undiagnosed, as of 2022.



Characteristics of Marylanders with an IDU Exposure Living with HIV

At the end of 2023, there were 4,432 people living with diagnosed HIV with IDU exposure.



- Of the 31,956 people living with diagnosed HIV in 2023, 13.9% were attributed to IDU exposure. Among males, 11.9% were attributed to IDU exposure and 5.0% to MMSC/IDU exposure. Among females, 17.7% were attributed to IDU exposure.
- 70.0% of people living with diagnosed HIV, attributed to IDU exposure, were ever diagnosed with Stage 3 (AIDS).
- Of the people living with diagnosed HIV attributed to IDU exposure, 78.0% had a viral load test result reported in 2023. Of those with a reported viral load test, 89.0% had a suppressed viral load.

NH: Non-Hispanic | IDU: Injection Drug Use | MMSC: Male-to-Male Sexual Contact

Share feedback on your fact sheet experience [here!](#)
Prevention and Health Promotion Administration
Maryland Department of Health
<https://health.maryland.gov/phpa/OIDEOR/CHSE>

Multiple imputation was used to estimate and adjust for missing exposure category. Data represents adults and adolescents (ages 13+) only.
Data source: Maryland Enhanced HIV/AIDS Reporting System (eHARS).
Data for 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing and care-related services.